Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Biogen Pharmachem Industries Ltd share price was up by 3.96% from the previous closing price of ₹1.01. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential payments due to Stoke. Biogen’s leadership has said they aren’t eager to deal, but ...

This data feed is not available at this time.

Dividend announcements are not available.